

2014

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

Matthew J. Ellis

Washington University School of Medicine in St. Louis

E. Mardis

Washington University School of Medicine in St. Louis

Tammi L. Vickery

Washington University School of Medicine in St. Louis

et al

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation

Ellis, Matthew J.; Mardis, E.; Vickery, Tammi L.; and et al, "Predicting response and survival in chemotherapy-treated triple-negative breast cancer." *British Journal of Cancer*. 111,8. 1532-1541. (2014). https://digitalcommons.wustl.edu/open_access_pubs/4036

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Keywords: breast cancer; genomics; subtypes; intrinsic; basal like; chemotherapy; neoadjuvant

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

A Prat^{*1,2}, A Lluch³, J Albanell^{4,5}, W T Barry⁶, C Fan⁷, J I Chacón⁸, J S Parker^{7,9}, L Calvo¹⁰, A Plazaola¹¹, A Arcusa¹², M A Seguí-Palmer¹³, O Burgues³, N Ribelles¹⁴, A Rodriguez-Lescure¹⁵, A Guerrero¹⁶, M Ruiz-Borrego¹⁷, B Munarriz¹⁸, J A López¹⁹, B Adamo¹, M C U Cheang⁷, Y Li⁷, Z Hu⁷, M L Gulley⁷, M J Vidal¹, B N Pitcher²⁰, M C Liu²¹, M L Citron²², M J Ellis²³, E Mardis²³, T Vickery²³, C A Hudis²⁴, E P Winer²⁵, L A Carey⁷, R Caballero²⁶, E Carrasco²⁶, M Martín^{26,27}, C M Perou^{7,9,28} and E Alba¹⁴

¹Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Pg Vall d'Hebron, 119-129, 08035 Barcelona, Spain; ²Department of Medicine, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain; ³Department of Medical Oncology and Department of Pathology, Hospital Clínic Universitari de Valencia, 46010 Valencia, Spain; ⁴Department of Medical Oncology, Hospital del Mar, IMIM, 08003 Barcelona, Spain; ⁵Department of Medical Oncology, Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain; ⁶Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; ⁷Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA; ⁸Department of Medical Oncology, Hospital Virgen de la Salud, 45004 Toledo, Spain; ⁹Department of Genetics, University of North Carolina, Chapel Hill, NC 27519, USA; ¹⁰Department of Medical Oncology, Complejo Hospitalario Universitario de A Coruña, 15002 A Coruña, Spain; ¹¹Department of Medical Oncology, Onkologikoa, 20014 San Sebastián, Spain; ¹²Department of Medical Oncology, Consorci Sanitari de Terrassa, 08225 Barcelona, Spain; ¹³Department of Medical Oncology, Corporació Sanitària Parc Taulí, 08208 Sabadell, Spain; ¹⁴Department of Medical Oncology and Department of Pathology, Hospital Universitario Virgen de la Victoria, 29010 Malaga, Spain; ¹⁵Department of Medical Oncology, Hospital General de Elche, 03203 Alicante, Spain; ¹⁶Department of Medical Oncology, Instituto Valenciano de Oncología (IVO), 46009 Valencia, Spain; ¹⁷Department of Medical Oncology, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain; ¹⁸Department of Medical Oncology, Hospital Universitario La Fe, 46026 Valencia, Spain; ¹⁹Department of Medical Oncology, Hospital San Camilo, 28006 Madrid, Spain; ²⁰Alliance Statistical and Data Center, Duke University, Durham, NC 27708, USA; ²¹Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA; ²²ProHEALTH Care Associates, LLP, Lake Success, NY 11803, USA; ²³Department of Oncology, Washington University, St. Louis, MO 63130, USA; ²⁴Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; ²⁵Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; ²⁶GEICAM (Spanish Breast Cancer Research Group), 28700 Madrid, Spain; ²⁷Department of Medical Oncology, Instituto de Investigación Sanitaria Hospital Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense, 28007 Madrid, Spain and ²⁸Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27519, USA

Background: In this study, we evaluated the ability of gene expression profiles to predict chemotherapy response and survival in triple-negative breast cancer (TNBC).

Methods: Gene expression and clinical–pathological data were evaluated in five independent cohorts, including three randomised clinical trials for a total of 1055 patients with TNBC, basal-like disease (BLBC) or both. Previously defined intrinsic molecular subtype and a proliferation signature were determined and tested. Each signature was tested using multivariable logistic regression models (for pCR (pathological complete response)) and Cox models (for survival). Within TNBC, interactions between each signature and the basal-like subtype (vs other subtypes) for predicting either pCR or survival were investigated.

Results: Within TNBC, all intrinsic subtypes were identified but BLBC predominated (55–81%). Significant associations between genomic signatures and response and survival after chemotherapy were only identified within BLBC and not within TNBC as a whole. In particular, high expression of a previously identified proliferation signature, or low expression of the luminal A signature, was found independently associated with pCR and improved survival following chemotherapy across different cohorts. Significant interaction tests were only obtained between each signature and the BLBC subtype for prediction of chemotherapy response or survival.

Conclusions: The proliferation signature predicts response and improved survival after chemotherapy, but only within BLBC. This highlights the clinical implications of TNBC heterogeneity, and suggests that future clinical trials focused on this phenotypic subtype should consider stratifying patients as having BLBC or not.

*Correspondence: Dr A Prat; E-mail: aprat@vhio.net

This work was presented, in part, as an oral communication at the ASCO 2012 annual meeting (Abstract #10500).

Received 6 April 2014; revised 26 June 2014; accepted 13 July 2014; published online 7 August 2014

© 2014 Cancer Research UK. All rights reserved 0007–0920/14



Triple-negative breast cancer (TNBC) is characterised by the absence of the therapeutically targetable hormone receptors and HER2 protein overexpression. For this reason, both adjuvant treatment and palliative therapy for metastatic TNBC is limited to chemotherapy. Although TNBC typically has higher rates of chemosensitivity compared with hormone receptor-positive breast cancer, it has a poor overall prognosis (Carey *et al*, 2007; Liedtke *et al*, 2008; Silver *et al*, 2010a) and there is no predictive biomarker of response or survival to allow tailored therapy for these patients.

Over the years, studies based on global gene expression analyses have identified five main intrinsic molecular subtypes of breast cancer known as luminal A, luminal B, HER2 enriched, basal like and claudin low (Perou *et al*, 2000; Sorlie *et al*, 2001; Prat *et al*, 2010, 2013a,b; Prat and Perou, 2011). Among them, the basal-like subtype (BLBC) comprises the majority of TNBC; however, the other 20–30% of TNBCs fall into other subtypes (Prat and Perou, 2011). Thus, significant molecular heterogeneity exists within TNBC and it is likely that improving clinical outcome and tailoring therapy will require further stratification by biologic subtype (Prat *et al*, 2013a).

In this study, we used gene expression data to classify multiple independent cohorts of patients from cooperative group trials and large multi-institution data sets into the main intrinsic molecular subtypes of breast cancer and then we evaluated the ability of various published gene expression profiles to predict response and/or survival following chemotherapy in TNBC and/or BLBC.

MATERIALS AND METHODS

Patients, samples and clinical data. Multiple data sets of TNBC or BLBC were evaluated (Table 1 and Supplementary Figure S1). For response prediction, we evaluated samples at diagnosis from two independent cohorts of patients treated with anthracycline/taxane-based chemotherapy in the neoadjuvant setting: the GEICAM/2006-03 Core-Basal phase II clinical trial (Alba *et al*, 2012) and a combined cohort of microarray studies previously published by the MDACC group (GSE25066 (Hatzis *et al*, 2011), GSE16716 (Popovici *et al*, 2010), GSE20271 (Tabchy *et al*, 2010), GSE23988 (Iwamoto *et al*, 2011) and MDACC133 (Hess *et al*, 2006)). For survival prediction, we evaluated samples from three independent cohorts of patients with primary breast cancer: the GEICAM/9906 and CALGB/9741 phase III clinical trials (Citron *et al*, 2003; Martín *et al*, 2008), and the METABRIC data set, which is a UK/Canadian cohort of nearly 2000 primary breast cancers with transcriptomic and outcome data (Curtis *et al*, 2012).

Characteristics of the patient populations evaluated have previously been described (Citron *et al*, 2003; Martín *et al*, 2008; Cheang *et al*, 2009; Nielsen *et al*, 2010; Alba *et al*, 2012) and are summarised in Table 1. The neoadjuvant cohorts had pathological complete response (pCR) in the breast (GEICAM/2006-03) and breast and axilla (MDACC based) as the primary end points. Patients in the GEICAM/2006-03 trial (NCT00432172) were randomised to neoadjuvant epirubicin/cyclophosphamide followed by docetaxel + / – carboplatin (Alba *et al*, 2012). In the MDACC-based cohort (Hess *et al*, 2006; Popovici *et al*, 2010; Tabchy *et al*, 2010; Hatzis *et al*, 2011; Iwamoto *et al*, 2011), all patients received neoadjuvant anthracycline/taxane-based chemotherapy. The adjuvant cohorts had disease-free survival (DFS), disease-specific survival (DSS) or relapse-free survival (RFS) as end points, and included GEICAM/9906 (Martín *et al*, 2008), in which patients with node-positive disease were randomly assigned to adjuvant 5-fluorouracil, epirubicin and cyclophosphamide (FEC) for six cycles vs FEC for four cycles followed by weekly paclitaxel for eight cycles, and CALGB/9741 (Citron *et al*, 2003), in which patients

with node-positive disease were randomly assigned to receive dose dense (every 2 weeks) vs conventional dosing (every 3 weeks) doxorubicin and (or followed by) cyclophosphamide followed by paclitaxel. The METABRIC cohort (Curtis *et al*, 2012) included patients who received either no adjuvant systemic therapy (AST) or adjuvant chemotherapy, although the exact regimens, doses and schedules are not available.

TNBC definition. The TNBC definition and cut points for oestrogen receptor (ER), progesterone receptor (PR) and HER2 were according to the 2007 and 2010 ASCO/CAP guidelines for HER2 (Wolff *et al*, 2006) and ER/PR (Hammond *et al*, 2010), respectively, in GEICAM/2006-03, MDACC-based and GEICAM/9906 data sets. In GEICAM/2006-03 and GEICAM/9906, the TNBC definition as well as Ki-67 immunohistochemical determination (clone MIB-1, DAKO, Carpinteria, CA, USA) were performed at a central laboratory and reviewed by two expert pathologists. In METABRIC and CALGB/9741, the pathological data were not centrally reviewed; thus, we decided to focus on those samples identified as BLBC by gene expression data.

Gene expression data. From GEICAM/2006-03, the PAM50 and claudin-low signatures were derived from a 543-gene set measured using the Nanostring nCounter platform (Nanostring Technologies, Seattle, WA, USA) from formalin-fixed paraffin-embedded (FFPE) tumour samples. For each sample, two 1 mm cores enriched with tumour tissue were obtained from the original tumour block, RNA was purified and ~100 ng of total was used to measure gene expression. Data were log base 2 transformed and normalised using five house-keeping genes (ACTB, MRPL19, PSMC4, RPLP0 and SF3A1). Raw gene expression data have been deposited in Gene Expression Omnibus (GSE58479).

From the MDACC Affymetrix (Affymetrix Inc., Santa Clara, CA, USA) U133A-based microarray cohort, publicly available gene expression data were obtained and normalised using MAS5 as previously reported (Usary *et al*, 2013; Prat *et al*, 2013a). From the METABRIC cohort, normalised microarray data were obtained from the European Genome-Phenome Archive (accession number: EGAS00000000083; Curtis *et al*, 2012). From GEICAM/9906, expression of the 50 PAM50 genes was measured using the qRT-PCR-based version as described previously (Bastien *et al*, 2012). Finally, expression of the 50 PAM50 genes, and the same five house-keeping genes used in GEICAM2006-03, was measured from CALGB/9741 using the nCounter platform from FFPE primary tumours (Liu *et al*, 2012).

Subtypes and gene signatures. All tumours were assigned to an intrinsic molecular subtype of breast cancer (luminal A, luminal B, HER2 enriched, BLBC and claudin low) and the normal-like group using the PAM50 subtype predictor and the claudin-low predictor (Parker *et al*, 2009; Nielsen *et al*, 2010; Prat *et al*, 2010), except for the GEICAM/9906 and CALGB/9741 data sets, in which only PAM50 50-gene data were available (Martín *et al*, 2008; Bastien *et al*, 2012). Of note, the same PAM50 and claudin-low training data sets (Parker *et al*, 2009; Prat *et al*, 2010) were used for subtype prediction in each test set.

Before subtyping, each individual data set was normalised accordingly (Perou *et al*, 2010). For GEICAM2006-03 and CALGB9741 data sets, both nCounter based, we had groups of tumour samples representative of each intrinsic subtype, which allowed us to estimate the platform-to-platform bias. For MDACC-based, METABRIC and GEICAM/9906 data sets, all of which have a large number of samples representative of all the intrinsic subtypes, we assumed that differences in the median expression of each gene were due to technical factors. Our subtype calls in MDACC-based and METABRIC data sets were highly concordant (kappa score 0.83 and 0.78) with the ones reported by

Table 1. Clinical–pathologic characteristics of the various breast cancer data sets evaluated

	GEICAM2006-03	MDACC based	GEICAM9906	METABRIC		CALG9741
Type of cohort	Core Basal ^a	Triple negative	Triple negative	PAM50 basal like		PAM50 basal like
Clinical setting	Neoadjuvant	Neoadjuvant	Adjuvant	Adjuvant		Adjuvant
Systemic treatment	Chemo	Chemo	Chemo	Chemo	None	Chemo
Chemoregimen	EC→D+/-Carbo	Anthracycline/taxane based	FEC or FEC→P	Various	—	Ax4→Tx4→Cx4 (3w vs 2w) ACx4→Tx4 (3w vs 2w)
Primary end point	pCR breast	pCR breast/axilla	DFS	DSS	DSS	RFS
No. of patients	69	188	100	185	199	314
Mean age	49.9	49.6	53.6	49.3	60.3	48.7
Node positivity	31 (44.9%) ^b	—	100 (100%)	157 (84.5%)	37 (19%)	314 (100%)
Tumour size >2 cm	62 (89.9%)	179 (95.2%)	71 (71.0%)	122 (67.4%)	103 (52.3%)	216 (69.0%)
Genomic Platform	nCounter	Microarray	qRT-PCR	Microarray	—	nCounter
Intrinsic subtype distribution						
Basal like	56 (81.2%)	109 (58%)	55 (55%)	140 (75.7%)	144 (72.4%)	314 (100%)
Claudin low	7 (10.1%)	47 (25%)	—	45 (24.3%)	55 (27.6%)	—
HER2 enriched	4 (5.8%)	14 (7.4%)	29 (29%)	—	—	—
Luminal A	0	3 (1.6%)	4 (4%)	—	—	—
Luminal B	0	6 (3.2%)	10 (10%)	—	—	—
Normal like	2 (2.9%)	9 (4.8%)	2 (2%)	—	—	—

Abbreviations: Carbo = carboplatin; DFS = disease-free survival; DSS = disease-specific survival; D = docetaxel; EC = epirubicin/cyclophosphamide; FEC = fluorouracil/epirubicin/cyclophosphamide; P = paclitaxel; pCR = pathological complete response; RFS = relapse-free survival; qRT-PCR = quantitative reverse transcription-PCR.

^aCentrally revised Core Basal pathology-based definition (ER/PR/HER2 negative, either CK5/6+ or EGFR+).

^bClinical nodal status assessment.

other investigators in their original publications (Hatzis *et al*, 2011; Curtis *et al*, 2012). PAM50 output data for these two data sets are provided in Supplementary Data. To further support that our normalisation approach was appropriate, we have provided a PC1 vs PC2 loading plot of the PAM50 genes and the different data sets evaluated (Supplementary Figure S2), including the PAM50 training data set used in all predictions.

Gene signatures evaluated were obtained from the PAM50 ($n = 8$ signatures) and claudin-low ($n = 1$) subtype predictors (Parker *et al*, 2009; Nielsen *et al*, 2010; Prat *et al*, 2010); from the PAM50 predictor, we evaluated the correlation coefficient of each sample to each subtype centroid (luminal A, luminal B, HER2 enriched, BLBC and normal). In addition, we also evaluated the previously reported proliferation score, which is the mean expression of 11 proliferation-related genes (Nielsen *et al*, 2010), and the risk of relapse (ROR) score, a continuous prognostic score based on subtype only (ROR-S), and based on subtype and proliferation (ROR-P; Nielsen *et al*, 2010). Finally, from the claudin-low predictor, we evaluated the Euclidian distance of each sample to the claudin-low 9-cell line centroid.

Statistical analysis. Biologic analysis of gene lists was performed with DAVID annotation tool (<http://david.abcc.ncifcrf.gov/>; Dennis *et al*, 2003). Association between the expression of each signature and pCR was assessed by logistic regression analyses adjusted for standard clinical–pathological variables. Survival functions to DSS, DFS and RFS were from the Kaplan–Meier product-limit estimator, with tests of differences by the log-rank test. Cox proportional hazard models adjusted for standard clinical–pathological variables were used to test the independent associations with survival of each gene or signature. All genes and gene signatures were evaluated as continuous variables. Finally, interaction tests between the expression of each signature and the BLBC (vs others) for pCR or survival outcome prediction were also evaluated in multivariable models.

RESULTS

Biologic heterogeneity within TNBC. To identify biological entities within TNBC, intrinsic molecular subtyping was performed on three different and independent cohorts (GEICAM/2006-03, MDACC based and GEICAM/9906) of 357 patients with primary TNBC (Table 1). All the intrinsic molecular subtypes were identified within TNBC, with BLBCs predominating (55–81.2%). Of note, in GEICAM/2006-03, eligibility included the ‘core basal’ definition (Nielsen *et al*, 2004), a more restrictive TNBC definition (that is, TNBC status plus immunostain positive for either cytokeratin 5/6 or EGFR). This cohort showed a significant enrichment for BLBCs compared with the triple-negative-only definition (81.2 vs 56.9%, $P < 0.001$, χ^2 -test).

To further explore the heterogeneity of BLBC (Supplementary Figure S3), we focused on the 56 tumours that were both TNBC and of the BLBC in the GEICAM/2006-03 cohort. Within this group, we identified 159 (29.7%) genes whose expression was found to have high variability (that is, >two-fold s.d.; Supplementary Table S1). Of these genes, 87 (54.7%) were also found to have high variability in TNBCs of the BLBC in the MDACC cohort. Among these, we identified a significant enrichment for genes involved in regulation of cell death (for example, CRYAB and INHBA), response to hormone stimulus (for example, FOXA1 and KRT19), cell migration (for example, FOXC1, IL8 and KIT), ectoderm development (for example, KRT14 and KRT5) and cell cycle (for example, CCND1, TP53 and BRCA1). In the GEICAM/2006-03 cohort, we also observed a wide range of Ki-67-positive tumour cells (35–95%; average 74%) in TNBC of the BLBC. Counter to prevailing dogma that all BLBCs are highly proliferative, there was a wide range of proliferation values within TNBC of the BLBC.

Predicting pCR after chemotherapy within TNBC. To identify predictors of chemotherapy response, we first evaluated gene expression-based signatures in the diagnostic (that is, pre-treatment) samples of the GEICAM/2006-03 trial (Alba *et al*, 2012). Among all patients, none of the signatures or clinical-pathological variables evaluated was found significantly associated with pCR (Figure 1A). Conversely, among patients with BLBC, high expression of the proliferation score, low expression of the luminal A signature and high Ki-67 by IHC were found to be significantly associated with pCR (Figure 1B). Interaction tests between each of these variables and the BLBC (*vs* others) for pCR showed a trend towards statistical significance for the luminal A signature (inverse relationship, $P=0.066$), the proliferation score ($P=0.062$) and no evidence of interaction with Ki-67 ($P=0.372$).

To confirm the findings obtained from GEICAM/2006-03, we interrogated 188 TNBC patients from the combined MDACC data sets treated neoadjuvantly with anthracycline/taxane-based chemotherapy. Similar to the data obtained in GEICAM/2006-03, none of the signatures was significantly associated with pCR within

TNBC (Figure 1C); however, the proliferation score and luminal A signature were again significantly associated with pCR within patients with TNBC of the BLBC (Figure 1D). Interaction tests within TNBC between each signature and the BLBC (*vs* others) for pCR were statistically significant (luminal A $P=0.023$; proliferation score $P=0.005$). Similar results were obtained in terms of DFS (Supplementary Figure S4). Ki-67 IHC data were not available from this data set.

Biological processes associated with pCR within TNBC of the BLBC subtype. To identify single genes whose expression might be associated with pCR, we evaluated the 56 TNBC of the BLBC subtype from the GEICAM/2006-03 trial. Among 535 genes assayed, the expression of 82 (15.3%) genes was significantly associated with pCR (Supplementary Table S2–4). Concordant with the previous findings using gene signatures, high expression of cell cycle-related genes (for example, CCNE1 and FANCA) and low expression of endocrine response-related genes (for example, PGR and FOXA1) were found significantly associated with pCR.




Figure 1. Adjusted odds ratios (ORs) for pathologic complete response (pCR) of various clinical-pathological variables and gene signatures (for unit increase) in (A) TNBC patients in GEICAM/2006-03, (B) TNBC and BLBC in GEICAM/2006-03, (C) TNBC patients in MDACC and (D) TNBC and BLBC in MDACC. The PAM50-based signatures represent either a correlation coefficient to a gene expression centroid (for basal like, HER2 enriched, luminal A, luminal B and normal) or a score (for RORS, proliferation score and RORP), and they are evaluated as continuous variables. The claudin-high signature represents an Euclidean distance to the claudin-low centroid, and it is evaluated as a continuous variable. Each signature has been standardised to have a mean of 0 and a s.d. of 1. The size of the square is inversely proportional to the s.e.; horizontal bars represent the 95% CIs of ORs. Statistically significant variables are shown in blue. Each gene signature has been evaluated individually after adjustment for standard clinical-pathological variables. The variables used for adjustment were treatment arm, age at diagnosis, nodal status and tumour size (GEICAM/2006-03); and tumour size, age at diagnosis and histological grade (MDACC).

In contrast, high expression of genes involved in epithelial-to-mesenchymal transition (for example, TWIST1 and ZEB1) was found to be significantly associated with lack of response (that is, residual disease).

To further explore these findings, we combined gene expression and clinical–pathological data of TNBC of the BLBC subtype from the GEICAM/2006-03 and MDACC-based cohorts (Supplementary Figure S5) and performed a multivariable logistic regression analysis for pCR prediction. Among 479 genes in common between these two platforms, 94 genes (19.6%) were found independently associated with pCR (Supplementary Data). Of these, 35 (37.2%) genes were identical to those identified in the GEICAM/2006-03 trial. Finally, the remainder ($n=59$ genes, 62.8%) tracked similar biology with endocrine response-related genes (for example, CCND1 and IL6) and cell cycle-related genes (for example, CHEK1 and CCNB1) being associated with chemoresistance and chemosensitivity, respectively.

Predicting DFS within TNBC. To evaluate whether the gene signatures predict survival, we evaluated clinical–pathological data and PAM50 50-gene qRT–PCR data from the GEICAM/9906 phase III trial (Martín *et al*, 2008), which included 100 patients with centrally reviewed TNBCs that received adjuvant chemotherapy. Within TNBC, no significant predictor of DFS was identified (Figure 2A). Conversely, within TNBCs of the BLBC subtype, the two previously identified signatures (that is, high expression of the proliferation score and low expression of luminal A signature) were found significantly associated with DFS, whereas Ki-67 by IHC was not (Figure 2B). Interaction tests within TNBC between each signature and the BLBC subtype (*vs* others) for DFS were statistically significant (luminal A $P=0.035$; proliferation score $P=0.017$).

To illustrate the results obtained in the GEICAM/9906 data set (Martín *et al*, 2008), we split the TNBC cohort, as well as the cohort of TNBCs of the BLBC subtype, into tertile groups based on the expression of the proliferation score. As expected, within the TNBC cohort, the ordinal proliferation score groups were not significantly associated with DFS (Figure 3A). Conversely, within those patients with TNBCs of the BLBC subtype, the proliferation tertile groups were found associated with DFS (Figure 3B) with an adjusted hazard ratio (HR) between the high *vs* low proliferation score tertile groups of 0.194 (0.056–0.669 95% confidence interval (CI)).

Predicting DSS within BLBC. We next evaluated gene expression and clinical–pathological data in the recently reported METABRIC cohort, which includes 185 and 199 patients with primary BLBC disease that received adjuvant chemotherapy and no AST, respectively (Curtis *et al*, 2012). Interestingly, in the no AST subgroup of patients, no genomic variable was found significantly associated with DSS (Figure 2C). Conversely, within the chemotherapy-treated subset of patients, proliferation score and the luminal A signature were found significantly associated with outcome (Figure 2D). Interaction tests within BLBC disease between each signature and the type of treatment (chemotherapy *vs* no AST) for DSS were found to be statistically significant (luminal A $P=0.014$; proliferation score $P=0.047$). In this data set, exclusion of the claudin-low samples did not alter the survival associations.

To further illustrate these findings, we split the BLBC/no AST subset of patients, and the BLBC/chemotherapy-treated subset of patients, into groups based on the expression of the proliferation score. As expected, within the no AST subset of patients, the groups were not found associated with DSS (Figure 3C) with an adjusted HR of the high *vs* low tertile group of 1.456 (0.680–3.209 95% CI). Conversely, within the chemotherapy-treated subset of patients, the groups were found associated with DSS (Figure 3D)

with an adjusted HR between the high *vs* low proliferation score groups of 0.410 (0.208–0.808 95% CI).

Independent evaluation in the CALGB/9741 clinical trial. Finally, we evaluated the association of gene expression and clinical–pathological data with RFS in 314 patients with primary BLBC from the CALGB/9741 study (Citron *et al*, 2003), in which patients were treated with adjuvant anthracycline/taxane-based chemotherapy. As in the previous cohorts, similar associations were observed with low expression of the luminal A signature ($P=0.038$) and high expression of the proliferation score ($P=0.067$) and ROR-P ($P=0.0493$) signatures being associated with better outcome (Figure 4A). To illustrate these results, we split patients into tertiles based on the expression of the proliferation score and plotted their RFS (Figure 4B). The adjusted HR between the high proliferation score group *vs* the intermediate and low groups was 0.509 (0.321–0.808 95% CI) and 0.611 (0.380–0.984 95% CI), respectively.

DISCUSSION

Over the years, BLBC has become more commonly known as TNBC; however, not all TNBCs are identified as BLBC by gene expression (Prat and Perou, 2011). In addition, the proportion of BLBCs within TNBC varies substantially from cohort to cohort (Prat and Perou, 2011; Table 1). Although this discrepancy could be explained by false-negative immunohistochemical results, the identification of all the intrinsic subtypes within centrally reviewed TNBC argues otherwise (Cheang *et al*, 2012). A potential explanation is that determination of three biomarkers for identifying the known intrinsic subtypes captures an inferior amount of biological diversity compared with assays that measure tens or hundreds of genes (Prat *et al*, 2012). It is now clear that significant biological heterogeneity exists within patients diagnosed with TNBC and additional efforts are needed to elucidate the clinical heterogeneity of this aggressive disease subtype as defined by these three biomarkers.

To address this need, we evaluated a selection of known prognostic signatures in patients with TNBC who received multiagent chemotherapy. In addition, we did so using multiple independent data sets and multiple genomic technologies. We found that all data sets and all technology platforms yielded the same result, namely, that only if we stratified TNBC into BLBC could we then identify patients with significantly better response (that is, pCR) and better survival using the evaluated biomarkers (that is, proliferation and correlation to LumA centroid); however, when using all TNBC patients, these predictive biomarkers were not useful, thus showing the value of first stratifying by biological group, and then second, by biomarker.

The association between high proliferation and chemotherapy benefit was not unexpected. Cytotoxic-based therapies are known to be more effective in highly proliferative tumours than in quiescent, low proliferative tumours (Skipper, 1971; Whitfield *et al*, 2006). Indeed, tumours with a higher percentage of Ki-67-positive tumour cells in the GEICAM/2006-03 trial responded more to chemotherapy than tumours with lower levels, although this association was not significant in interaction testing while the genomic-based proliferation signature was. This is concordant with two previous reports where patients with TNBC and higher percentage of Ki-67-positive tumour cells showed higher pCR rates than those with lower Ki-67 levels (Adamo and Anders, 2011; Fasching *et al*, 2011; Keam *et al*, 2011). Supporting these results, Silver *et al* (2010b) identified a proliferation-related gene signature of the E2F3-related transcription factor that was associated with response to neoadjuvant cisplatin in TNBC, all of which had a BLBC gene expression profile. In addition, in a pooled cohort study




Figure 2. Adjusted survival HRs of various clinical-pathological variables and gene signatures (for unit increase) in (A) TNBC and (B) TNBC and BLBC treated with adjuvant chemotherapy in GEICAM/9906, (C) BLBC not treated with adjuvant chemotherapy in METABRIC and (D) BLBC treated with adjuvant chemotherapy in METABRIC. The PAM50-based signatures represent either a correlation coefficient to a gene expression centroid (for basal like, HER2 enriched, luminal A, luminal B and normal) or a score (for RORS, proliferation score and RORP), and they are evaluated as continuous variables. The claudin-high signature represents an Euclidean distance to the claudin-low centroid, and it is evaluated as a continuous variable. Each signature has been standardised to have a mean of 0 and a s.d. of 1. The size of the square is inversely proportional to the s.e.; horizontal bars represent the 95% CIs of HRs. Statistically significant variables are shown in blue. Each gene signature has been evaluated individually after adjustment for standard clinical-pathological variables. The variables used for adjustment were treatment arm, age at diagnosis, nodal status and tumour size (GEICAM/9906); and tumour size, age at diagnosis and nodal status (METABRIC).

(Ignatiadis *et al.*, 2012), the investigators found that this E2F3-related signature and other signatures of chromosomal instability and PTEN loss were associated with increased pCR in ER – /HER2 – tumours; however, these signatures were not found significantly associated with pCR in BLBC (Ignatiadis *et al.*, 2012).

Recently, Lehmann *et al.* (2011) identified seven different subtypes of TNBC by global gene expression analysis (basal 1 (BL1), basal 2 (BL2), immunomodulatory (IM), luminal androgen receptor (LAR), mesenchymal (M), mesenchymal stem cell (MSL) and unstable (UNS)). When compared with the intrinsic subtypes of breast cancer, BL1, BL2, IM and M largely fall within the BLBC subtype, whereas LAR largely falls within the non-BLBC subtypes (Lehmann *et al.*, 2011; Prat *et al.*, 2013a; Mayer *et al.*, 2014). The intrinsic subtype distribution within the MSL group is less clear (Lehmann *et al.*, 2011; Mayer *et al.*, 2014). In any case, the seven-subtype classification of TNBC, as a group, has been found associated with pCR in an independent cohort of 143 patients with TNBC treated with anthracycline/taxane-based chemotherapy (Masuda *et al.*, 2013). Among the different subtypes, BL1, which is characterised by high expression of cell cycle-related genes (Lehmann *et al.*, 2011), showed the highest pCR rates (52%),

whereas BL2 and LAR subtypes showed the lowest pCR rates (0 and 10%; Masuda *et al.*, 2013). However, no significant association with survival outcomes was observed among the seven subtypes in this chemotherapy-treated data set (Masuda *et al.*, 2013). We were not able to assay these seven subtypes across all our studies presented here, as some of our studies only had data for the 50 PAM50 genes; however, further studies are needed to determine whether the BLBC tumours with high or low expression of the luminal A or proliferation signature belong to one of these potential molecular entities.

The results presented here may have potential clinical implications for the management of patients with TNBC. First, we provide additional evidence that TNBCs are a heterogeneous disease entity and that subclassification of TNBC into phenotypic subsets can help predict chemotherapy response and survival. This argues that clinical trials evaluating TNBC should consider using gene expression data to stratify patients by the different molecular entities given the impact of this heterogeneity on the primary end points of these trials. Second, high-risk tumours of the BLBC subtype with high proliferation scores are very sensitive to chemotherapy and it may be possible that the typical standard of care treatment for this group is effective (anthracycline/taxane neo/




Figure 3. Kaplan–Meier survival analysis in GEICAM/9906 and METABRIC data sets based on the PAM50 proliferation score. Patients with (A) TNBC and (B) TNBC and BLBC treated with adjuvant chemotherapy in GEICAM/9906, (C) BLBC not treated with adjuvant systemic chemotherapy (no AST) in METABRIC and (D) BLBC treated with adjuvant chemotherapy (CT) in METABRIC.




Figure 4. Associations of clinical–pathological variables and gene signatures with RFS in 314 patients with BLBC of the CALGB/9741 cohort. (A) Adjusted survival HRs of various clinical–pathological variables and gene signatures (for unit increase). The PAM50-based signatures represent either a correlation coefficient to a gene expression centroid (for basal like, HER2 enriched, luminal A, luminal B and normal) or a score (for RORS, proliferation score and RORP), and they are evaluated as continuous variables. The claudin-high signature represents an Euclidean distance to the claudin-low centroid, and it is evaluated as a continuous variable. Each signature has been standardised to have a mean of 0 and a s.d. of 1. The size of the square is inversely proportional to the s.e.; horizontal bars represent the 95% CIs of HRs. Statistically significant variables are shown in blue. The variables used for adjustment were treatment arm, age at diagnosis, nodal status and tumour size. (B) Kaplan–Meier survival analysis in the subset of patients with BLBC in the CALGB/9741 data set based on the PAM50 proliferation score (using tertiles).

adjuvant regimens). If so, future studies might aim to limit toxicity while maintaining or enhancing efficacy. Conversely, those predicted to be less responsive, or to have a worse prognosis, may be appropriate for studies of novel agents or approaches. Some patients might be particularly sensitive to specific additional drugs like platinum agents, which increase pCR rates in TNBC (Sikov *et al*, 2013; Von Minckwitz *et al*, 2013), or other cytotoxics,

as will be tested in the upcoming CIBOMA/2004-01/GEICAM/2003-11 phase III clinical trial that focuses on adjuvant capecitabine maintenance therapy after conventional induction chemotherapy in 876 patients with TNBC. Novel therapies that target lower-proliferating cells (that is, mesenchymal/claudin-low-like and/or luminal-like cells) might be warranted in patients with TN tumours of the BLBC subtype that show low expression of

proliferation features, and also those TNBCs that are of the luminal lineage.

There are several caveats to our study. First, this is a retrospective study involving heterogeneous patient populations and the data need to be confirmed in prospective clinical trial(s). Second, none of the survival data sets came from a randomised clinical trial of adjuvant chemotherapy vs no adjuvant chemotherapy. Thus, the true predictive value of these signatures was only evaluated in the neoadjuvant setting (GEICAM/2006-03 and MDACC), where pCR has been found to be an intermediate biomarker for outcome but one robust enough, particularly in TNBC, to be considered for registrational trials by the FDA. In support of the predictive nature of these signatures, none predicted outcome in patients with BLBCs who did not receive systemic adjuvant therapy in the METABRIC cohort. Third, in the GEICAM/9906 and CALGB/9741 cohorts, we only had PAM50 50-gene data, and thus we were not able to test whether further identification of the claudin-low subtype (and other TNBC signatures) might have improved the survival predictions. Fourth, the common markers of the applied platforms/cohort are mainly restricted to genes expressed by the carcinoma cells. Thus, the analyses could miss signals from the microenvironment, which have been shown to be predictive both for pCR (Rody *et al*, 2009; Ignatiadis *et al*, 2012) and survival (Rody *et al*, 2011). Finally, patients from each of the data sets received different anthracycline- or anthracycline/taxane-based chemotherapy regimens, schedules and doses, and thus the ability of the signatures to predict response to particular treatment strategies could not be tested.

Another important consideration of our study is that we did not attempt to identify an optimal cutoff for the various biomarkers (that is, signatures) evaluated but rather focused on the association of the continuous expression of each biomarker with each end point. The main reason is that different gene expression-based platforms and protocols were used in each cohort and thus, standardisation of a biomarker cut point would have been difficult to achieve and most likely unreliable. In any case, the fact that all five data sets gave very similar associations, and were found independently of the platform/protocol used, argues in favour of a true biologically based robust finding.

Genomic signatures of proliferation and luminal subtype are associated with response to chemotherapy in the neoadjuvant setting and with outcome following chemotherapy in TNBC, but only within those belonging to the BLBC subtype. TNBC is biologically heterogeneous, and improving therapy may require tumour stratification based on the BLBC vs non-BLBC gene expression profile.

ACKNOWLEDGEMENTS

This work was supported by funds from the NCI Breast SPORE program Grant No. P50-CA58223-09A1 (CMP), by RO1-CA138255 (CMP), by the Breast Cancer Research Foundation (CMP and MJE), National Cancer Institute (NCI) Strategic Partnering to Evaluate Cancer Signatures Grant No. U01 CA114722-01 (MJE), by the Sociedad Española de Oncología Médica (AP), by FEDER (RETICC-RD12/0036/0051, RD12/0036/0042, RD12/0036/0076, RD12/0036/0070), by Instituto de Salud Carlos III—PI13/01718 (AP), by Banco Bilbao Vizcaya Argentaria (BBVA) Foundation (AP) and by the Alliance Statistics and Data Center (U10-CA33601).

CONFLICT OF INTEREST

CMP and MJE are equity stock holders of BioClassifier LLC and University Genomics. CMP, MJE, MCUC and JSP have filed a

patent on the PAM50 assay. MLG serves as a consultant for Roche Molecular Systems. Uncompensated advisory role of AP for Nanostring Technologies. The remaining authors declare no conflict of interest.

REFERENCES

- Adamo B, Anders C (2011) Stratifying triple-negative breast cancer: which definition(s) to use? *Breast Cancer Res* **13**: 105.
- Alba E, Chacon J, Lluch A, Anton A, Estevez L, Cirauqui B, Carrasco E, Calvo L, Segui M, Ribelles N, Alvarez R, Sanchez-Muñoz A, Sanchez R, Garcia-Asenjo J, Rodriguez-Martin C, Escudero M, Albanell J (2012) A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. *Breast Cancer Res Treat* **136**: 487–493.
- Bastien RR, Rodriguez-Lescure A, Ebbert MT, Prat A, Munarriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Alvarez I, Dowell T, Wall D, Segui M, Barley L, Boucher K, Alba E, Pappas L, Davis C, Aranda I, Fauron C, Stijleman I, Palacios J, Anton A, Carrasco E, Caballero R, Ellis M, Nielsen T, Perou C, Astill M, Bernard P, Martin M (2012) PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. *BMC Med Genomics* **5**: 44.
- Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Lollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. *Clin Cancer Res* **13**: 2329–2334.
- Cheang M, Martin M, Nielsen T, Prat A, Rodriguez-Lescure A, Ruiz A, Chia S, Shepherd L, Voduc D, Bernard P, Ellis M, Perou C, Di Leo A, Carey L (2012) Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: a collaborative effort of the BIG-NCI NABC. *Proceedings of the American Society of Clinical Oncology*, 1–5 June 2012; Chicago, IL, USA, a1008.
- Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. *J Natl Cancer Inst* **101**: 736–750.
- Citron ML, Berry DA, Cirincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. *J Clin Oncol* **21**: 1431–1439.
- Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowitz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale A-L, Brenton JD, Tavare S, Caldas C, Aparicio S (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* **486**: 346–352.
- Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA (2003) DAVID: database for annotation, visualization, and integrated discovery. *Genome Biol* **4**: R60.
- Fasching P, Heusinger K, Haerle L, Niklos M, Hein A, Bayer C, Rauh C, Schulz-Wendtland R, Bani M, Schrauder M, Kahmann L, Lux M, Strehl J, Hartmann A, Dimmler A, Beckmann M, Wachter D (2011) Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. *BMC Cancer* **11**: 486.
- Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FCG, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *J Clin Oncol* **28**: 2784–2795.
- Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W,

- Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF (2011) A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. *JAMA* **305**: 1873–1881.
- Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gomez HL, Hortobagyi GN, Puzstai L (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. *J Clin Oncol* **24**: 4236–4244.
- Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, Andre F, Loi S, Piccart M, Michiels S, Sotiriou C (2012) Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. *J Clin Oncol* **30**: 1996–2004.
- Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Ya-Hui Shiang C, Santarpia L, Matsuoka J, Hortobagyi GN, Symmans WF, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Andre F, Simon R, Puzstai L (2011) Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. *J Natl Cancer Inst* **103**(3): 264–272.
- Keam B, Im S, Lee K, Han S (2011) Ki-67 can be used for further classification of triple-negative breast cancer into two subtypes with different response and prognosis. *Breast Cancer Res* **13**: R22.
- Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest* **121**: 2750–2767.
- Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Puzstai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. *J Clin Oncol* **26**: 1275–1281.
- Liu M, Pitcher B, Mardis E, Davies S, Snider J, Vickery T, Reed J, DeSchryver K, Singh B, Friedman P, Gradishar W, Perez E, Martino S, Citron M, Norton L, Winer E, Hudis C, Perou C, Ellis M, Barry W (2012) PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy. *San Antonio Breast Cancer Symposium*; 4–8 December 2012; San Antonio, TX, USA, P2-10-01.
- Martin M, Rodríguez-Lescure Á, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Muñoz-Árriiz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JJ, Antón A, Baena JM, Plazaola A, Modolell A, Pelegri A, Mel JR, Aranda E, Adrover E, Álvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM (2008) Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. *J Natl Cancer Inst* **100**: 805–814.
- Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT (2013) Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. *Clin Cancer Res* **19**: 5533–5540.
- Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA (2014) New strategies for triple-negative breast cancer—deciphering the heterogeneity. *Clin Cancer Res* **20**: 782–790.
- Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akshen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. *Clin Cancer Res* **10**: 5367–5374.
- Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman JJ, Reed J, Cheang MCU, Mardis ER, Perou CM, Bernard PS, Ellis MJ (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. *Clin Cancer Res* **16**: 5222–5232.
- Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman JJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. *J Clin Oncol* **27**: 1160–1167.
- Perou CM, Parker JS, Prat A, Ellis MJ, Bernard PS (2010) Clinical implementation of the intrinsic subtypes of breast cancer. *Lancet Oncol* **11**: 718–719.
- Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akshen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale A-L, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. *Nature* **406**: 747–752.
- Popovici V, Chen W, Gallas B, Hatzis C, Shi W, Samuelson F, Nikolsky Y, Tsyganova M, Ishkin A, Nikolskaya T (2010) Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. *Breast Cancer Res* **12**: R5.
- Prat A, Adamo B, Cheang MCU, Anders CK, Carey LA, Perou CM (2013a) Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. *Oncologist* **18**: 123–133.
- Prat A, Cheang MCU, Martin M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Perou CM (2013b) Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. *J Clin Oncol* **31**: 203–209.
- Prat A, Parker J, Fan C, Perou C (2012) PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. *Breast Cancer Res Treat* **135**: 301–306.
- Prat A, Parker J, Karginova O, Fan C, Livasy C, Herschkowitz J, He X, Perou C (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. *Breast Cancer Res* **12**: R68.
- Prat A, Perou CM (2011) Deconstructing the molecular portraits of breast cancer. *Mol Oncol* **5**: 5–23.
- Rody A, Holtrich U, Puzstai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hankaer L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M (2009) T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. *Breast Cancer Res* **11**: R15.
- Rody A, Karn T, Liedtke C, Puzstai L, Ruckhaeberle E, Hankaer L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Muller V, Holtrich U, Kaufmann M (2011) A clinically relevant gene signature in triple negative and basal-like breast cancer. *Breast Cancer Res* **13**: R97.
- Sikov W, Berry D, Perou C, Singh B, Cirincione C, Tolanev S, Kuzma C, Pluard T, Somlo G, Port E, Golshan M, Bellon J, Collyar D, Hahn O, Carey L, Hudis C, Winer E (2013) Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). *San Antonio Breast Cancer Symposium*; 10–14 December 2013; San Antonio, TX, USA, S5-01.
- Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong C-O, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE (2010a) Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. *J Clin Oncol* **28**: 1145–1153.
- Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong C-O, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE (2010b) Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. *J Clin Oncol* **28**: 1145–1153.
- Skipper HE (1971) Kinetic behavior versus response to chemotherapy. *Natl Cancer Inst Monogr* **34**: 2–14.
- Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen M, van de Rijn M, Jeffrey S, Thorsen T, Quist H, Matese J, Brown P, Botstein D, Eystein Lonning P, Borresen-Dale A (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci USA* **98**: 10869–10874.
- Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, Symmans WF, Puzstai L (2010) Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. *Clin Cancer Res* **16**: 5351–5361.
- Usary J, Zhao W, Darr D, Roberts PJ, Liu M, Balletta L, Karginova O, Jordan J, Combest A, Bridges A, Prat A, Cheang MCU, Herschkowitz JI, Rosen JM, Zamboni W, Sharpless NE, Perou CM (2013) Predicting drug responsiveness in human cancers using genetically engineered mice. *Clin Cancer Res* **19**: 4889–4899.

Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, Kummel S, Eidtmann H, Klare P, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching PA, Sinn BV, Engels K, Mehta K, Nekljudova V, Untch M (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. *Lancet Oncol* **15**: 747–756.

Whitfield M, George L, Grant G, Perou C (2006) Common markers of proliferation. *Nat Rev Cancer* **6**: 99.

Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S,

Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2006) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. *J Clin Oncol* **25**: 118–145.



This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0/>

Supplementary Information accompanies this paper on British Journal of Cancer website (<http://www.nature.com/bjc>)